Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Pharmaron Acquires US Phase I/II Clinical CRO from Shin Nippon

publication date: Feb 28, 2017
Pharmaron, a Beijing CRO, has signed a definitive agreement to acquire a majority stake in Shin Nippon Biomedical Laboratories Clinical Pharmacology Center of Maryland. SNBL CPC, which opened in 2005, provides moderate and highly complex Phase I/II clinical development services in the University of Maryland BioPark. It has completed over 200 studies. Shin Nippon will retain a minority stake in the lab. The Maryland facility will be integrated with Pharmaron's existing US clinical CROs in Louisville, Kentucky and Los Angeles, plus a facility in the UK. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital